No Cover Image

Journal article 47 views 14 downloads

The use of benchmark dose uncertainty measurements for robust comparative potency analyses / Ryan Wheeldon; Stephen D. Dertinger; Steven M. Bryce; Jeffrey C. Bemis; George Johnson

Environmental and Molecular Mutagenesis, Volume: 62, Issue: 3, Pages: 203 - 215

Swansea University Authors: Ryan, Wheeldon, George, Johnson

  • 56076 VOR.em.22422.pdf

    PDF | Version of Record

    Distributed under the terms of a Creative Commons Attribution 4.0 License (CC-BY).

    Download (2.58MB)

Check full text

DOI (Published version): 10.1002/em.22422

Abstract

The Benchmark Dose (BMD) method is the favored approach for quantitative dose–response analysis where uncertainty measurements are delineated between the upper (BMDU) and lower (BMDL) confidence bounds, or confidence intervals (CIs). Little has been published on the accurate interpretation of uncert...

Full description

Published in: Environmental and Molecular Mutagenesis
ISSN: 0893-6692 1098-2280
Published: Wiley 2021
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa56076
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract: The Benchmark Dose (BMD) method is the favored approach for quantitative dose–response analysis where uncertainty measurements are delineated between the upper (BMDU) and lower (BMDL) confidence bounds, or confidence intervals (CIs). Little has been published on the accurate interpretation of uncertainty measurements for potency comparative analyses between different test conditions. We highlight this by revisiting a previously published comparative in vitro genotoxicity dataset for human lymphoblastoid TK6 cells that were exposed to each of 10 clastogens in the presence and absence (+/−) of low concentration (0.25%) S9, and scored for p53, γH2AX and Relative Nuclei Count (RNC) responses at two timepoints (Tian et al., 2020). The researchers utilized BMD point estimates in potency comparative analysis between S9 treatment conditions. Here we highlight a shortcoming that the use of BMD point estimates can mischaracterize potency differences between systems. We reanalyzed the dose responses by BMD modeling using PROAST v69.1. We used the resulting BMDL and BMDU metrics to calculate “S9 potency ratio confidence intervals” that compare the relative potency of compounds +/− S9 as more statistically robust metrics for comparative potency measurements compared to BMD point estimate ratios. We performed unsupervised hierarchical clustering that identified four S9‐dependent groupings: high and low‐level potentiation, no effect, and diminution. This work demonstrates the importance of using BMD uncertainty measurements in potency comparative analyses between test conditions. Irrespective of the source of the data, we propose a stepwise approach when performing BMD modeling in comparative potency analyses between test conditions.
Keywords: BMD, comparative, DNA damage, potency, uncertainty
College: Swansea University Medical School
Issue: 3
Start Page: 203
End Page: 215